Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological
features and treatments. Although the overall survival (OS) of patients with ALL has recently …

Background With the recent advances in the understanding of the interaction of the immune
system with developing tumor, it has become imperative to consider the immunological …

Preclinical and emerging clinical studies demonstrate that bispecific T-cell engaging (BiTE)
antibody constructs can potently lyse targeted tumor cells, but the determinants for their …

Intrinsic immune responses to acute leukemia are inhibited by a variety of mechanisms,
such as aberrant antigen expression by leukemia cells, secretion of immunosuppressive …

Background: Possible correlations between the expression of immune checkpoint molecules
and prognosis in childhood acute leukemia were investigated. Materials and Methods: The …

The adoptive transfer of chimeric antigen receptor T (CAR T) cells have been recognized as
a promising therapeutic strategy for the treatment of hematological malignancies; however …

Background Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous
disease characterized by different molecular subtypes with different prognosis and response …

ABSTRACT Introduction Glioblastoma Multiforme (GBM) is one of the fatal cancers of the
Central Nervous System (CNS). A variety of reasons exist for why previous immunotherapy …

The success of immunotherapy has highlighted the critical role of the immune
microenvironment in acute lymphoblastic leukemia (ALL); however, the immune landscape …

ABSTRACT Introduction Hematological Malignancies (HMs) are a group of progressive,
difficult-to-treat, and highly recurrent diseases. A suppressed phenotype of the immune …